鉄欠乏性貧血市場- 世界の産業規模、シェア、動向、機会、予測、治療タイプ別、治療分野別、エンドユーザー別、地域別、競合別、2020-2030F

世界の鉄欠乏性貧血（IDA）市場は、2024年に51億4,000万米ドルと評価され、予測期間中にCAGR 6.68％で成長し、2030年には75億9,000万米ドルに達すると予測されています。

より広範なヘルスケア展望の中の主要セグメントとして、IDA市場は、世界的に多様な年齢層や人口集団で鉄欠乏性貧血が広く普及していることから、その複雑さと重要性の増大によって定義されています。

この市場には、IDAの多面的な性質に対処するために設計された診断ソリューション、治療法、支持療法製品が幅広く含まれます。IDAの潜在的な健康影響とともに、IDAを取り巻く意識の高まりがマーケット成長を促す大きな要因となっています。世界のヘルスケアシステムが進化し、医療サービスへのアクセスが改善するにつれて、早期スクリーニングと診断率が上昇し、革新的な治療オプションに対する需要が高まっています。これに対応するため、製薬企業やヘルスケアプロバイダーは、診断能力や治療的介入を向上させるための研究開発に多額の投資を行っています。

市場促進要因

鉄欠乏性貧血の世界的普及率の上昇

主な市場課題

経済格差とヘルスケアへのアクセス制限

これらの課題を克服するには、的を絞った政策介入、ヘルスケア資金の拡大、すべての人口層における手頃な価格の診断薬・治療薬への公平なアクセスが必要です。

主な市場動向

治療選択肢の革新と多様化

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の鉄欠乏性貧血市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 治療の種類別（経口鉄剤療法、非経口鉄剤療法、赤血球輸血、その他）
  • 治療領域別（産婦人科、腫瘍学、うっ血性心不全（CHF）、炎症性腸疾患、腎臓、その他）
  • エンドユーザー別（病院・診療所、外来診療センター、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ
  • 治療の種類別
  • 治療領域別
  • エンドユーザー別
  • 地域別

第5章 アジア太平洋地域の鉄欠乏性貧血市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 治療の種類別
  • 治療領域別
  • エンドユーザー別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州の鉄欠乏性貧血市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米の鉄欠乏性貧血市場展望

• 市場規模・予測
• 市場シェア・予測
  • 治療の種類
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米の鉄欠乏性貧血市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカの鉄欠乏性貧血市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第12章 世界の鉄欠乏性貧血市場：SWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Daiichi Sankyo Company
• Novartis AG
• Rockwell Medical Inc
• Iron4u Aps
• AbbVie Inc
• Sanofi
• Disc Medicine Inc
• Pfizer Inc
• Akebia Therapeutics
• Keros Therapeutics Inc

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Iron deficiency anemia (IDA) market was valued at USD 5.14 billion in 2024 and is projected to reach USD 7.59 billion by 2030, growing at a CAGR of 6.68% during the forecast period. As a key segment within the broader healthcare landscape, the IDA market is defined by its complexity and growing significance, given the widespread prevalence of iron deficiency anemia across diverse age groups and populations globally.

This market encompasses a broad spectrum of diagnostic solutions, therapeutic treatments, and supportive care products designed to address the multifaceted nature of IDA. Increased awareness surrounding the condition, along with its potential health consequences, is a major catalyst driving market growth. As global healthcare systems evolve and access to medical services improves, early screening and diagnosis rates are rising-resulting in greater demand for innovative treatment options. In response, pharmaceutical companies and healthcare providers are significantly investing in research and development to advance diagnostic capabilities and therapeutic interventions.

Key Market Drivers

Increasing Global Prevalence of Iron Deficiency Anemia

The escalating prevalence of IDA is one of the most significant growth drivers for the global market. Iron deficiency anemia continues to represent a major global health challenge, impacting individuals across all demographics.

Shifts in dietary habits are a key contributor. Modern diets often lack sufficient iron-rich foods, such as red meats and leafy greens, and are increasingly reliant on processed or nutrient-deficient alternatives. The growing adoption of vegetarian and vegan diets, while beneficial for various reasons, may lack heme iron-a form more readily absorbed by the body-further heightening the risk of deficiency. This has fueled demand for iron supplements, fortified foods, and other nutritional solutions.

Additionally, the rising incidence of chronic health conditions has increased vulnerability to IDA. Gastrointestinal disorders such as inflammatory bowel disease and celiac disease can inhibit iron absorption, while chronic inflammation can limit iron availability for red blood cell production. As these underlying health issues become more widespread, the need for effective IDA diagnostics and treatments continues to grow.

Key Market Challenges

Economic Inequality and Limited Access to Healthcare

Despite being a global concern, iron deficiency anemia disproportionately affects individuals in low-income and underserved regions due to economic and healthcare disparities. These disparities present considerable obstacles to diagnosis, treatment, and overall disease management.

In many developing countries, access to basic medical services remains limited. Regular health screenings and affordable diagnostic testing are often unavailable, resulting in delayed or missed diagnoses. Even when symptoms are recognized, financial constraints frequently prevent individuals from seeking care or purchasing prescribed treatments.

The affordability and consistent availability of iron supplements-a cornerstone of IDA management-pose an additional challenge. In rural or resource-limited settings, these products may be prohibitively expensive or entirely inaccessible. Vulnerable groups, including pregnant women, infants, and children, are particularly affected, with untreated IDA leading to complications such as preterm birth and developmental delays.

Overcoming these challenges requires targeted policy interventions, expanded healthcare funding, and equitable access to affordable diagnostics and treatments across all population segments.

Key Market Trends

Innovation and Diversification in Treatment Options

Ongoing advancements in IDA treatment have significantly diversified and strengthened the global market. While traditional iron supplements-available in oral, liquid, and intravenous forms-remain central to care, new formulations are improving bioavailability and reducing adverse side effects, thus enhancing patient adherence and outcomes.

Innovative treatments such as erythropoiesis-stimulating agents (ESAs) have transformed the management of moderate to severe anemia. These therapies promote red blood cell production, reducing reliance on blood transfusions and offering a more sustainable, patient-friendly option.

Moreover, targeted therapies are emerging to address specific underlying causes of iron deficiency. For example, patients with gastrointestinal disorders that limit iron absorption now have access to specialized treatments designed to optimize iron uptake and utilization. This personalized approach not only improves treatment efficacy but also expands the market by accommodating the diverse clinical needs of the patient population.

Pharmaceutical firms and healthcare organizations continue to invest in research and innovation, enhancing the overall ecosystem for IDA management. This evolution of therapeutic offerings is broadening the market's reach and solidifying its long-term growth potential.

Key Market Players

• Daiichi Sankyo Company
• Novartis AG
• Rockwell Medical Inc
• Iron4u Aps
• AbbVie Inc
• Sanofi
• Disc Medicine Inc
• Pfizer Inc
• Akebia Therapeutics
• Keros Therapeutics Inc

Report Scope:

In this report, the Global Iron Deficiency Anemia Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Iron Deficiency Anemia Market, By Therapy Type:

• Oral Iron Therapy
• Parenteral Iron Therapy
• Red Blood Cell Transfusion
• Others

Iron Deficiency Anemia Market, By Therapy Areas:

• Obstetrics and Gynecology
• Oncology
• Congestive Heart Failure (CHF)
• Inflammatory Bowel Disease
• Renal
• Others

Iron Deficiency Anemia Market, By End User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Iron Deficiency Anemia Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Iron Deficiency Anemia Market.

Available Customizations:

Global Iron Deficiency Anemia Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Iron Deficiency Anemia Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Therapy Type (Oral Iron Therapy, Parenteral Iron Therapy, Red Blood Cell Transfusion, Others)
  • 4.2.2. By Therapy Areas (Obstetrics and Gynecology, Oncology, Congestive Heart Failure (CHF), Inflammatory Bowel Disease, Renal, Others)
  • 4.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 4.2.4. By Region
  • 4.2.5. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Therapy Type
  • 4.3.2. By Therapy Areas
  • 4.3.3. By End User
  • 4.3.4. By Region

5. Asia Pacific Iron Deficiency Anemia Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapy Type
  • 5.2.2. By Therapy Areas
  • 5.2.3. By End User
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Iron Deficiency Anemia Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Therapy Type
      • 5.3.1.2.2. By Therapy Areas
      • 5.3.1.2.3. By End User
  • 5.3.2. India Iron Deficiency Anemia Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Therapy Type
      • 5.3.2.2.2. By Therapy Areas
      • 5.3.2.2.3. By End User
  • 5.3.3. Australia Iron Deficiency Anemia Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Therapy Type
      • 5.3.3.2.2. By Therapy Areas
      • 5.3.3.2.3. By End User
  • 5.3.4. Japan Iron Deficiency Anemia Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Therapy Type
      • 5.3.4.2.2. By Therapy Areas
      • 5.3.4.2.3. By End User
  • 5.3.5. South Korea Iron Deficiency Anemia Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Therapy Type
      • 5.3.5.2.2. By Therapy Areas
      • 5.3.5.2.3. By End User

6. Europe Iron Deficiency Anemia Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapy Type
  • 6.2.2. By Therapy Areas
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Iron Deficiency Anemia Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapy Type
      • 6.3.1.2.2. By Therapy Areas
      • 6.3.1.2.3. By End User
  • 6.3.2. Germany Iron Deficiency Anemia Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapy Type
      • 6.3.2.2.2. By Therapy Areas
      • 6.3.2.2.3. By End User
  • 6.3.3. Spain Iron Deficiency Anemia Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapy Type
      • 6.3.3.2.2. By Therapy Areas
      • 6.3.3.2.3. By End User
  • 6.3.4. Italy Iron Deficiency Anemia Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Therapy Type
      • 6.3.4.2.2. By Therapy Areas
      • 6.3.4.2.3. By End User
  • 6.3.5. United Kingdom Iron Deficiency Anemia Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Therapy Type
      • 6.3.5.2.2. By Therapy Areas
      • 6.3.5.2.3. By End User

7. North America Iron Deficiency Anemia Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Therapy Type
  • 7.2.2. Therapy Type
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Iron Deficiency Anemia Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapy Type
      • 7.3.1.2.2. By Therapy Areas
      • 7.3.1.2.3. By End User
  • 7.3.2. Mexico Iron Deficiency Anemia Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapy Type
      • 7.3.2.2.2. By Therapy Areas
      • 7.3.2.2.3. By End User
  • 7.3.3. Canada Iron Deficiency Anemia Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapy Type
      • 7.3.3.2.2. By Therapy Areas
      • 7.3.3.2.3. By End User

8. South America Iron Deficiency Anemia Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapy Type
  • 8.2.2. By Therapy Areas
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Iron Deficiency Anemia Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapy Type
      • 8.3.1.2.2. By Therapy Areas
      • 8.3.1.2.3. By End User
  • 8.3.2. Argentina Iron Deficiency Anemia Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapy Type
      • 8.3.2.2.2. By Therapy Areas
      • 8.3.2.2.3. By End User
  • 8.3.3. Colombia Iron Deficiency Anemia Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapy Type
      • 8.3.3.2.2. By Therapy Areas
      • 8.3.3.2.3. By End User

9. Middle East and Africa Iron Deficiency Anemia Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapy Type
  • 9.2.2. By Therapy Areas
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Iron Deficiency Anemia Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapy Type
      • 9.3.1.2.2. By Therapy Areas
      • 9.3.1.2.3. By End User
  • 9.3.2. Saudi Arabia Iron Deficiency Anemia Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapy Type
      • 9.3.2.2.2. By Therapy Areas
      • 9.3.2.2.3. By End User
  • 9.3.3. UAE Iron Deficiency Anemia Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapy Type
      • 9.3.3.2.2. By Therapy Areas
      • 9.3.3.2.3. By End User

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Iron Deficiency Anemia Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Daiichi Sankyo Company
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Novartis AG
• 14.3. Rockwell Medical Inc
• 14.4. Iron4u Aps
• 14.5. AbbVie Inc
• 14.6. Sanofi
• 14.7. Disc Medicine Inc
• 14.8. Pfizer Inc
• 14.9. Akebia Therapeutics
• 14.10.Keros Therapeutics Inc

15. Strategic Recommendations

16. About Us & Disclaimer